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Abstract 
Purpose: To evaluate the clinical effect of bushenhuazhuo (a Chinese traditional medicine) in 
combination with ciprofloxacin (an orthodox medicine) in chronic prostatitis (CP) therapy. 
Methods: A total of 160 patients who suffered from CP and received treatment in the People’s Hospital 
of Zhengzhou between April 2012 and June 2014 were selected and divided randomly into treatment 
and control groups, with 80 patients in each group. Control group was given 0.25 g ciprofloxacin 
hydrochloride tablets twice a day for 4 weeks. In addition to ciprofloxacin administration, patients in the 
treatment group also received a dose of bushenhuazhuo preparation twice daily for 4 weeks. Clinical 
outcomes, quality of life as well as lecithin body and white blood cell (WBC) count in expressed prostatic 
secretions (EPS-WBC) were evaluated. 
Results: Cure rates in the treatment and control groups were 90 and 72.50 %, respectively; this 
difference was significant (p < 0.05). Scores for National Institutes of Health Chronic Prostatitis 
Symptom Index (NIH-CPSI), WBC, and lecithin bodies in the treatment group (8.20 ± 2.20 points, 4.50 ± 
1.20 points, and 28.10 ± 2.10 points, respectively) were higher (p < 0.05) than for the control group 
(12.20 ± 2.20, 6.30 ± 2.20, and 23.30 ± 2.90 points, respectively). The levels of interferon (IFN)-γ and 
tumour necrosis factor (TNF)-α in the treatment group (26.20 ± 3.30 and 33.80 ± 5.40 mg/L, 
respectively) were lower than those in the control group (37.70 ± 3.90 and 48.40 ± 3.70 mg/L, 
respectively), whereas the level of interleukin (IL)-10 in the treatment group (292.60 ± 23.70 mg/L) was 
higher (p < 0.05) than that in control group (235.80 ± 25.90 mg/L). 
Conclusion: Ciprofloxacin combined with the Chinese traditional medicine, bushenhuazhuo 
preparation, demonstrates a marked therapeutic effect in CP. Its mechanism of action may be related to 
decreased levels of IFN-γ and TNF-α and increased IL-10. 
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Chronic prostatitis (CP), one of the most 
commonly seen diseases in the male urogenital 
system, accounts for one-third of men’s 
diseases; it usually occurs in the age range of 20 
- 40 years, develops slowly, and is difficult to 
cure. It can impact severely the quality of life of 
sufferers [1,2]. CP features a long course, 
common recurrence, and a complex pathological 
mechanism; the symptoms of paruria and 
perineal pain clinically can result in sexual 
dysfunction and infertility if the treatment is 
delayed [3,4]. The effects of currently available 
Western medicines have not been satisfactory. 
 
Modern medicine considers that CP can be 
divided into chronic bacterial prostatitis, non-
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bacterial prostatitis, and prostatodynia according 
to the Meares - Stamey classification [5]. In 
1995, the United States National Institutes of 
Health (NIH) proposed dividing prostatitis into 
category I, category II (chronic bacterial 
prostatitis), category III (chronic pelvic pain 
syndrome or chronic abacterial prostatitis), and 
category IV (asymptomatic inflammatory 
prostatitis) [6]. Category III accounts for 90 % of 
cases. 
 
Traditional Chinese medicine classifies CP into 
the categories of Lin and Zhuo, or the categories 
of kidney vacuity and lumbar pain, impotence, 
prospermia, and retention of urine. Traditional 
Chinese medicine considers CP as induced 
primarily by insecurity of the essence gate, 
stagnation of humid heat, and liver depression. 
Based on the clinical experience, we used a 
Chinese traditional medicine, bushenhuazhuo 
preparation, in combination with ciprofloxacin to 






A total of 160 CP patients who received 
treatment at the People’s Hospital of Zhengzhou 
between April 2012 and June 2014 were 
selected randomly and divided into control and 
treatment groups, 80 in each. In the treatment 
group, patients aged from 29 to 64 years (mean 
38.70 ± 10.20 years) had developed CP over the 
previous 2 months to 6 years (mean 1.50 ± 0.60 
years) and in the control group, patients aged 
from 28 to 62 years (average 36.90 ± 8.20 years) 
had developed CP over the previous 3 months to 
7 years (average 1.70 ± 0.50 years). 
 
Patients who met the diagnostic criteria of CP [8], 
underwent no other treatment or had stopped 
receiving another treatment for more than 1 
week, and signed an informed consent were 
included. Patients with a history of treatment for 
benign prostatic hyperplasia, prostate cancer, 
deformity of the urethra or prostate, or laser, 
radio-frequency, microwave, or ablation 
treatment, who had acute onset of CP and who 
developed severe cardiovascular and 
cerebrovascular diseases or liver and renal 
diseases were excluded. No significant 
difference was found in general data (P > 0.05); 
thus, the results were comparable. This study 
was approved by the medical ethics committee of 
People’s Hospital of Zhengzhou (approval no. 
PHZ20150425QXW). It was conducted according 




Patients in the control group were administered 
ciprofloxacin hydrochloride tablets orally 
(Tianfang Pharmacy Inc., Henan; branch no. 
H41024142), 0.25 g twice a day for 4 weeks. In 
addition to ciprofloxacin therapy, patients in the 
treatment group were also given bushenhuazhuo 
preparation. Bushenhuazhuo preparation was 
comprised of prepared rehmannia root (20 g), 
fructus psoraleae (10 g), corydalis yanhusuo (10 
g), radix cyathulae (15 g), semen plantaginis (15 
g), Dioscorea tokoro Makino (10 g), herba 
patriniae (15 g), golden cypress (10 g), rhizoma 
acori graminei (10 g), Poria cocos (20 g), 
bighead atractylodes rhizome (15 g), salviae 
miltiorrhizae (15 g), and lotus plumule (10 g); a 
dose each was administered orally twice daily. 
Again, 4 weeks was regarded as one course. 
Patients were forbidden from taking irritable 





The NIH Chronic Prostatitis Symptom Index 
(NIH-CPSI) was used. Moreover, conventional 
microscopy of prostate fluid was performed; 
specifically, the numbers of white blood cells 
(WBCs) and lecithin bodies were determined in 
five high-power fields. Levels of interferon (IFN)-
γ, tumour necrosis factor (TNF)-α, and interleukin 
(IL)-10 in prostate fluid were detected with 
enzyme linked immunosorbent assays (ELISAs) 
using kits (Wuhan Boster Bioengineering, Inc.). 
The values above were evaluated once before 
and after treatment. 
 
Criteria for a therapeutic effect 
 
The comprehensive therapy standard, based on 
NIH-CPSI [10], was adopted. If the NIH-CPSI 
score declined by not less than 90 %, prostate 
fluid was found to be normal in two examinations, 
pressure pain disappeared, and the results of 
bacterial cultures were negative, then CP was 
considered ‘cured.’ If the NIH-CPSI score 
decreased by not less than 60 %, pressure pain 
improved significantly, the levels of WBCs in 
prostate were reduced to not less than 60 % in 
two examinations, and the result of bacterial 
cultures were negative, then the treatment was 
considered to be markedly effective.  
 
If the NIH-CPSI score decreased by more than 
30 %, pressure pain was relieved, the levels of 
WBCs in prostate fluid was reduced by not less 
than 30 % in two consecutive examinations, and 
bacteria grew, then the treatment was 
considered effective. If the NIH-CPSI score was 
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reduced by less than 30 %, pressure pain 
showed no improvement, the levels of WBCs in 
prostate fluid declined by less than 30 % in two 
examinations, and bacteria grew, then the 
treatment was considered ineffective. The 
equation for response rate is as follows:  
 
d = [(a+b+c)/n] × 100………………. (1) 
 
where d is the response rate, a is the number of 
‘cured’ patients, b is the number of patients 
obtaining a significant effect, c is the number of 
patients obtaining an effect, and n is the total 




The SPSS software (ver. 19.0) was used for all 
analyses. The data are expressed as mean ± 
standard deviation (SD). Comparison between 
groups was performed using t-test. Numerical 
data were processed using χ2 tests. Correlations 
were analysed using Spearman’s correlation 
analysis. Differences were considered 




Comparison of therapeutic effect 
 
Table 1 shows that 50 patients were cured, 18 
cases were significantly effective, 4 cases were 
effective, and 8 cases were ineffective in the 
treatment group, and 34 patients were cured, 10 
cases were significantly effective, 14 cases were 
effective, and 22 cases were ineffective in the 
control group. The total response rate of the 
treatment group (90 %) was higher than that of 
the control group; the difference was statistically 
significant (p < 0.05). 
 
NIH-CPSI scores before and after treatment 
 
Table 2 shows that NIH-CPSI scores in both 
groups declined significantly after treatment, and 
the scores in the treatment group were lower 
than those of the control group after treatment (p 
< 0.05). No significant difference was found in 
scores for pain, discomfort, or urinary symptom, 
but the score for quality of life showed a 
significant difference between the groups (p < 
0.05). 
 
WBCs and lecithin bodies 
 
Table 3 shows that the numbers of WBCs in the 
treatment group were lower than those in the 
control group; the difference was significant (p < 
0.05). Moreover, the number of lecithin bodies in 
the treatment group was higher than in the 
control group (p < 0.05). 
 
IFN-γ, TNF-α and IL-10 levels before and after 
treatment 
Table 4 shows that levels of IFN-γ, TNF-α, and 
IL-10 improved in both groups after treatment (p 
< 0.05). The improvement in the treatment group 
was more obvious than in the control group (p < 
0.05). 
 
    Table 1: Comparison of clinical effect between two groups (n) 
 
Group n Cure Very effective Effective Ineffective Total cure rate (%) 
Control  80 34 10 14 22 72.50 
Treatment  80 50 18 4 8 90.00* 
      Note: *P < 0.05, vs. control group 
 
     Table 2: NIH-CPSI scores before and after treatment (mean ± SD) 
 
Group Time Pain or discomfort 
Urinary 
symptom Quality of life Total 
Control  
(n=80) 
Before  13.20±2.90 5.00±1.30 8.80±2.20 16.10±4.70 
After  6.80±2.40△ 4.90±1.40△ 4.10±1.90△ 12.20±2.20△ 
Treatment 
(n=80) 
Before 12.50±3.20 4.20±1.60 7.20±2.20 15.20±4.70 
After 4.60±2.30△ 3.10±1.40△ 1.80±1.00△# 8.20±2.20△# 
    Note: △ P < 0.05, vs. before treatment (within group); # p < 0.05, vs. control group after treatment. 
 
Table 3: WBCs and lecithin bodies in expressed prostatic secretions (EPS) before and after treatment (mean ± 
SD, n/HP) 
 
Group n Time WBCs Lecithin bodies 
Control  80 Before  15.80±2.80 7.30±2.20 80 After  6.30±2.20△ 23.30±2.90△ 
Treatment  80 Before  16.10±3.10 7.20±2.50 80 After  4.50±1.20△# 28.10±2.10△# 
      Note: △P < 0.05, vs. before treatment (within group), # P < 0.05, vs. control group after treatment 
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Table 4: IFN-γ, TNF-α and IL-10 levels in prostate fluid before and after treatment (mean ± SD, mg/L) 
 
Group n Time IFN-γ IL-10 TNF-α 
Control  80 Before  44.50±4.70 188.10±23.50 71.70±6.90 80 After  37.70±3.90△ 235.80±25.90△ 48.40±3.70△ 
Treatment  80 Before  46.50±4.60 184.50±28.40 70.30±7.50 80 After  26.2±3.30△# 292.6±23.70△# 33.80±5.40△# 




The pathogenesis of CP remains controversial. 
Most scholars consider that the occurrence of CP 
is associated with infection by pathogenic 
microorganisms, paruria, stimulation of urine, 
anxious emotions, neuroendocrine dyscrasia, 
immune reaction abnormalities, oxidative stress, 
and pelvic disease [11]. Unconventional sexual 
activities, excessive drinking, long-term intake of 
irritable foods, fatigue, and long-term extrusion of 
pelvic floor muscles are also considered to be 
associated with CP. In clinical practice, anti-
bacterial treatment is the major therapy for 
prostatitis; however, its curative effect is not 
satisfactory, which may be due to the unique 
anatomical structure of the prostate. Other 
factors, such as redundant prepuce and 
iatrogenic injuries, such as in catheterisations, 
may also induce CP. CP is associated with drug 
permeation inhibition and inflammatory 
secretions induced by the barrier function of the 
prostatic capsule [12]. 
 
Incorrect use of anti-bacterial drugs will weaken 
their curative effect and may even lead to 
dysbiosis and liver and kidney damage. As the 
effects of antibiotics alone are limited, currently, 
traditional Chinese medicines in combination with 
Western medicines are used extensively in 
treating CP. In the view of traditional Chinese 
medicine, CP belongs to categories of turbid 
semen, turbid urine, and stranguria and is 
induced by the long-term existence of wet-heat, 
the stagnation of qi, and blood stasis [13]. 
Traditional Chinese medicine is effective in the 
treatment of CP. It has been shown that 
traditional Chinese medicines can resist 
inflammation, infection, and fibrosis, improving 
microcirculation, urodynamics, and immunity, 
and regulation of the pH value of prostatic fluid 
[14]. 
 
It has been shown that essence exists in the 
kidney and spleen; qi deficiency can result in 
interior dampness accumulation and turbidity; 
pain is induced by wetness and heat, and kidney 
qi damage can result in seminal emissions [15]. 
CP may be induced by smoking, excessive 
drinking, masturbation, the withdrawal method, 
and frequent feculent sexual intercourse. The 
pathogenesis of CP includes wet-heat, stasis, 
essence stasis, and kidney deficiency. Wet, heat, 
stasis, and qi deficiency are all involved in the 
pathological process of CP. Wet-heat dominates 
in the early stage of CP; stasis and qi deficiency 
dominate in the middle and later stages of CP.  
 
Prepared rehmannia root can benefit the 
essence and fill the marrow. Fructus psoraleae 
can the warm kidney and support yang. Semen 
plantaginis, herba patriniae, Dioscorea tokoro 
Makino, golden cypress, and rhizoma acori 
graminei, which can clear heat, eliminate 
wetness, and relieve pain, can effectively relieve 
the clinical symptoms of prostatitis. Moreover, 
Poria cocos can clear dampness, tonify the 
spleen, calm the nerves, and quiet the heart. 
Bighead atractylodes rhizome can tonify the qi 
and spleen and eliminate wetness. The 
combination of the two drugs can function in 
tonifying the spleen and eliminating dampness 
[16]. Corydalis yanhusuo can promote qi to 
activate the blood, and salviae miltiorrhizae can 
promote blood circulation to remove blood stasis; 
they are both useful in improving blood 
circulation [17]. Radix cyathulae can remove 
blood stasis and stimulate menstrual flow. Lotus 
plumule, which can clear heart heat, calm liver 
heat, and remove spleen heat, is effective in 
relieving patient anxiety [18]. The preparation 
has functions of tonifying qi and the kidney, 
eliminating wetness, clearing heat, activating the 
blood, and dispersing blood stasis. This study 
showed that the treatment group had a higher 
total response rate than the control group; 
moreover, scores for quality of life and levels of 
WBCs and lecithin bodies in the treatment group 
were superior to those in the control group. 
 
Microscopic research of CP has become a 
hotspot of research, and cell factors are key [19]. 
In this study, an initial exploration was made 
regarding the mechanism of action of CP 
treatment by assessing levels of IFN-γ, TNF-α, 
and IL-10 before and after treatment. Cell factors 
function in regulating the immune response and 
mediating inflammatory reactions. IFN-γ and 
TNF-α, secreted by Th1 cells, are pro-
inflammatory, whereas IL-10, secreted by Th2 
cells, is anti-inflammatory. The balance between 
Th1 and Th2 can ensure the immune function of 
the human body and influence pathological 
development and transformation [20]. 
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IFN-γ can induce the activation of macrophages; 
the active substances secreted can damage 
endothelial cells, strengthen the immune 
response, and promote the progression of 
inflammatory reactions. TNF-α can promote the 
adhesion of neutrophil granulocytes on 
endothelial cells and mediate the generation of 
adherence factor and inflammatory mediators 
[21]. IL-10 can inhibit T cell - mediated 
inflammatory response. It has been found that 
the level of IL-10 correlates with clinical 
symptoms in patients [22]; the study suggested 
that bushenhuazhuo preparation could lower 
levels of IFN-γ and TNF-α and increase the level 
of IL-10, which may be an important mechanism 
worthy of further study.  
 
Limitation of the study 
 
The number of cases in the present study was 
small, which may have influenced the results. 
Thus, studies with larger sample sizes should be 




Bushenhuazhuo preparation, a Chinese 
traditional medicine, can significantly improve 
local microcirculation, relieve local symptoms 
induced by CP, and enhance the localised 
concentration of orally administered ciprofloxacin 
in the prostate. The drug combination did not 
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